{"slug":"pd-l1","tag":"pd-l1","variants":["pd-l1"],"description":"No description yet","count":5,"kinds":{"person":1,"biomarker":4},"related":[{"slug":"biomarker","tag":"biomarker","shared":4},{"slug":"discovery","tag":"discovery","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1}],"records":[{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","tldr":"Discovered PD-L1 (B7-H1) and showed tumours use it to escape immunity, the biology behind every anti-PD-1 drug."},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","tldr":"CPS counts every PD-L1-stained cell in the tumour, immune cells included, and divides by the number of tumour cells. Pembrolizumab labels use CPS 1 or CPS 10 as the gate in head and neck, stomach, oesophageal, cervical, ovarian and triple-negative breast cancer."},{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/","tldr":"TPS is the share of tumour cells whose membrane stains for PD-L1, ignoring immune cells. In lung cancer it decides whether pembrolizumab or cemiplimab can be given alone: 1 percent opens the door, 50 percent is where single-agent treatment is strongest."},{"id":"pd-l1-ic-score","kind":"biomarker","name":"PD-L1 IC score (immune-cell score, SP142)","route":"/biomarkers/pd-l1-ic-score/","tldr":"The IC score measures how much of the tumour area is covered by PD-L1-stained immune cells rather than tumour cells. It belongs to the SP142 assay used with atezolizumab and is read differently from every other PD-L1 score."},{"id":"pd-l1-tc-score","kind":"biomarker","name":"PD-L1 TC score (tumour-cell score, SP263 and 28-8)","route":"/biomarkers/pd-l1-tc-score/","tldr":"The TC score is the percentage of tumour cells staining for PD-L1 on the SP263 or 28-8 assays. Atezolizumab uses 1 percent after lung surgery and 50 percent for first-line treatment alone; nivolumab with ipilimumab uses 1 percent in first-line lung cancer."}]}